Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06140108
Other study ID # 00002
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date December 15, 2023
Est. completion date March 30, 2024

Study information

Verified date April 2024
Source SINA Health Education and Welfare Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

this is open labelled randomize control trial among women with PCOS. PCOS, an endocrine condition, affects 5%-15% of premenopausal women. PCOS is characterized by atypical menstruation, ovulation difficulties, hyperandrogenemia, insulin resistance, and other metabolic abnormalities. Metformin is now an option for PCOS. The clinical reactions to metformin are limited and varied. Novel SGLT2 inhibitors treat type 2 diabetes with weight loss, insulin resistance reduction, and cardiovascular benefits. There is little evidence on SGLT2 inhibitor effectiveness in PCOS patients.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date March 30, 2024
Est. primary completion date March 30, 2024
Accepts healthy volunteers No
Gender Female
Age group 15 Years to 49 Years
Eligibility Inclusion Criteria: 1. All women participants belong to the reproductive age group, i.e., 18 to 45 years will be included in the study. 2. All those women of BMI of greater than 25 kg/m2 will be included in this study 3. Women with a diagnosis of PCOS by using two (hyperandrogenism and oligo-anovulation) out of three (oligo-anovulation, hyperandrogenism and polycystic ovaries) Rotterdam criteria 2 which confirm hyperandrogenism (acne, seborrhea, hair loss on the scalp, increased body or facial hair) on clinical judgement will be included in the study 4. Those who documented and self-reported oligomenorrhea (cycle length greater than 35 days and nine or fewer periods per year) will be included. or 5. Those who report amenorrhea (absence of menses for a period of 3 months) will be inclusion criteria of the study. 6- PCO Women with or without comorbidity or Multimorbidity specifically, Hypothyroidism, Diabetes, Hypertension. - Exclusion Criteria: 1. Women of non-classical 21-hydroxylase deficiency, hyperprolactinemia, Cushing's disease, or androgen- secreting tumors will be streaked from participating. 2. In addition to this, Pregnancy or intent to become pregnant, breastfeeding, documented use of oral hormonal contraceptives and hormone- releasing implants, clomiphene citrate or oestrogen modulators, gonadotropin-releasing hormone (GnRH) modulators and Minoxidil will be excluded. 3. History or presence of malignant neoplasms within the last one years, pancreatitis (acute or chronic) will also be excluded from the study 4. Women with recurrent complaint of urinary tract infection (UTI)will be excluded from the study. -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Empagliflozin 10 MG
Each participant will receive empagliflozin 10mg daily for 3 months.
MetFORMIN 500 Mg Oral Tablet
Each participant will receive metformin 1000mg daily for 3 months.

Locations

Country Name City State
Pakistan SINA Yousuf Sb Goth Karachi Sindh

Sponsors (1)

Lead Sponsor Collaborator
SINA Health Education and Welfare Trust

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Irregular menstruations assessment Assessment of Irregular menstruation measured by menstruations lasts 2 to 7 days after three months of treatment with either empagliflozin 10mg or metformin 1000mg daily. Three months treatment with either empagliflozin 10mg or metformin 1000mg daily
Secondary Body weight assessment of change in Body weight in Kg after three months treatment with either empagliflozin 10mg or metformin 1000mg daily Three months treatment with either empagliflozin 10mg or metformin 1000mg daily
Secondary Systolic Blood Pressure (SBP) assessment of change in SBP in mm/Hg after three months treatment with either empagliflozin 10mg or metformin 1000mg daily Three months treatment with either empagliflozin 10mg or metformin 1000mg daily
Secondary Lipid profile measured through biochemical test assessment of change in Blood Pressure in mg/dL after three months treatment with either empagliflozin 10mg or metformin 1000mg daily Three months treatment with either empagliflozin 10mg or metformin 1000mg daily
Secondary Hb1c test assessment of change in Hb1c level in percentage after three months treatment with either empagliflozin 10mg or metformin 1000mg daily Three months treatment with either empagliflozin 10mg or metformin 1000mg daily
Secondary fasting blood-glucose measured through biochemical test assessment of fasting blood-glucose in mmol/L after three months treatment with either empagliflozin 10mg or metformin 1000mg daily Three months treatment with either empagliflozin 10mg or metformin 1000mg daily
Secondary Diastolic Blood Pressure (DBP) assessment of change in DBP in mm/Hg after three months treatment with either empagliflozin 10mg or metformin 1000mg daily Three months treatment with either empagliflozin 10mg or metformin 1000mg daily
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Completed NCT06158932 - A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04932070 - Berberine and Polycystic Ovary Syndrome N/A
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT03480022 - Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS Phase 3
Active, not recruiting NCT03043924 - Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT05246306 - Aerobic Capacity and Physical Fitness Level of Adolescents With PCOS
Completed NCT05981742 - Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS Phase 2
Completed NCT05702957 - Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome Phase 2/Phase 3
Completed NCT05029492 - Effect of Visceral Manipulation on PCOS N/A
Completed NCT02924025 - Motivational Interviewing as an Intervention for PCOS N/A
Not yet recruiting NCT02255578 - Endobarrier Treatment in Women With PCOS Phase 3
Not yet recruiting NCT00883259 - Metformin and Gestational Diabetes in High-risk Patients: a RCTs Phase 4
Withdrawn NCT01638988 - Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin Phase 3
Completed NCT02098668 - Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON N/A
Completed NCT01462864 - Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome N/A
Recruiting NCT01431352 - Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT00989781 - Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome N/A